Skip to main content

Daniel Alvarez De la Sierra

Institutions of which they are part

Research technician
Translational Immunology
Vall Hebron Institut de Recerca

Daniel Alvarez De la Sierra

Institutions of which they are part

Research technician
Translational Immunology
Vall Hebron Institut de Recerca

Projects

COVID-19, PERFIL INMUNOLÓGICO DE RIESGO

IP: -
Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino, Romina Dieli Crimi, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

RECEPTORES INHBITORIOS (NEGATIVE IMMUNE CHECKPOINT RECEPTORS, NCRs) EN AUTOINMUNIDAD TIROIDEA Y CANCER, NUEVAS VÍAS TERAPÉUTICAS EN AUTOINMUNIDAD

IP: -
Collaborators: Oscar González López, Roser Ferrer Costa, Carmela Iglesias i Felip, Anna Casteras Román, Elena Garralda Cabanas, Daniel Alvarez De la Sierra
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI17/00324
Duration: 01/01/2018 - 30/06/2022

Sol·licitud de les beques Predoctorals. Modalitat VHIR-MIR

IP: Sol·licitud de les beques Predoctorals. Modalitat VHIR-MIR
Collaborators: Daniel Alvarez De la Sierra
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-16-34/ALVAREZ
Duration: 22/05/2017 - 21/05/2020

Diferencias inmunológicas en la Artritis idiopática Juvenil en relación a la respuesta al tratamiento antiTNF entre población pediátrica y adulta con especial atención a la inmunogenicidad

IP: -
Collaborators: Daniel Alvarez De la Sierra
Funding agency: Instituto de Salud Carlos III
Funding: 57475
Reference: PI13/00857
Duration: 01/01/2014 - 30/06/2018

Related news

A study from the Vall d’Hebron Campus demonstrates that the Ex Vivo C5b-9 deposition test is useful for monitoring the activity of the complement system (CS) in patients with aHUS or transplant-associated TMA.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

Related professionals

Maria Laura  Monterde Alvarez

Maria Laura Monterde Alvarez

Research technician
Growth and Development
Read more
Adrián Tirado Herranz

Adrián Tirado Herranz

Read more
Herena Eixarch Ahufinger

Herena Eixarch Ahufinger

Postdoctoral researcher
Clinical Neuroimmunology
Read more
Marta Esteban Bachs

Marta Esteban Bachs

Tècnic/a Grau Superior
Fundraising Unit
Communication Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.